Review



gene set enrichment analysis of biocarta pathways  (BioCarta)

 
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    BioCarta gene set enrichment analysis of biocarta pathways
    Gene Set Enrichment Analysis Of Biocarta Pathways, supplied by BioCarta, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/gene+set+enrichment+analysis+of+biocarta+pathways/entrez+gene+versions+of+the+biocarta+gene+sets/10__1158_slash_2159___8290__cd___19___0529-571-19-19
    Average 90 stars, based on 1 article reviews
    gene set enrichment analysis of biocarta pathways - by Bioz Stars, 2026-11
    90/100 stars

    Images

    Related Articles

    Genome Wide:

    Article Title: ID1 Mediates Escape from TGFβ Tumor Suppression in Pancreatic Cancer
    Article Snippet: .. C) Genes enriched in the genome-wide screen were ranked by (direction * p-value) and gene set enrichment analysis of Biocarta pathways was performed. .. D) MSK-IMPACT mutations mutually exclusive to TGF-β pathway alterations were analyzed via cBioPortal and ranked by –log10(p-value) for mutual exclusivity.



    Similar Products

    gene set enrichment analysis of biocarta pathways  (BioCarta)
    90
    BioCarta gene set enrichment analysis of biocarta pathways
    Gene Set Enrichment Analysis Of Biocarta Pathways, supplied by BioCarta, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/gene+set+enrichment+analysis+of+biocarta+pathways/entrez+gene+versions+of+the+biocarta+gene+sets/10__1158_slash_2159___8290__cd___19___0529-571-19-19
    Average 90 stars, based on 1 article reviews
    gene set enrichment analysis of biocarta pathways - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier
    gene set enrichment analysis biocarta signaling pathway signatures  (BioCarta)
    90
    BioCarta gene set enrichment analysis biocarta signaling pathway signatures
    ( A ) Feature availability among the TCGA (orange), WFCCC (purple), and MDACC (blue) cohorts. Feature names are shown at the right. Unavailable features are labeled in gray. ( B ) Pairwise associations among features in the ER module presented in . The yellow box highlights common associations shared by two groups of associations. ( C ) Patient subtyping using the <t>BioCarta</t> <t>signatures</t> (top region) associated with the ER module. These signatures revealed four subtypes: Immune Inert, Neutral, Active, and Responsive. ( D ) Differential treatment responses assessed by Kaplan-Meier survival analysis of the WFCCC cohort, using distant-metastasis-free survival time as the index. Survival curves of the Immune Neutral (top) and Active (bottom) Subtypes under different treatments are presented and labeled with patient numbers and log-rank test p-values. More details are given in the Supplement.
    Gene Set Enrichment Analysis Biocarta Signaling Pathway Signatures, supplied by BioCarta, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/gene+set+enrichment+analysis+of+biocarta+pathways/gene+set+enrichment+analysis+biocarta+signaling+pathway+signatures/pmc04947904-157-15-15
    Average 90 stars, based on 1 article reviews
    gene set enrichment analysis biocarta signaling pathway signatures - by Bioz Stars, 2026-11
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    ( A ) Feature availability among the TCGA (orange), WFCCC (purple), and MDACC (blue) cohorts. Feature names are shown at the right. Unavailable features are labeled in gray. ( B ) Pairwise associations among features in the ER module presented in . The yellow box highlights common associations shared by two groups of associations. ( C ) Patient subtyping using the BioCarta signatures (top region) associated with the ER module. These signatures revealed four subtypes: Immune Inert, Neutral, Active, and Responsive. ( D ) Differential treatment responses assessed by Kaplan-Meier survival analysis of the WFCCC cohort, using distant-metastasis-free survival time as the index. Survival curves of the Immune Neutral (top) and Active (bottom) Subtypes under different treatments are presented and labeled with patient numbers and log-rank test p-values. More details are given in the Supplement.

    Journal: Scientific Reports

    Article Title: Relational Network for Knowledge Discovery through Heterogeneous Biomedical and Clinical Features

    doi: 10.1038/srep29915

    Figure Lengend Snippet: ( A ) Feature availability among the TCGA (orange), WFCCC (purple), and MDACC (blue) cohorts. Feature names are shown at the right. Unavailable features are labeled in gray. ( B ) Pairwise associations among features in the ER module presented in . The yellow box highlights common associations shared by two groups of associations. ( C ) Patient subtyping using the BioCarta signatures (top region) associated with the ER module. These signatures revealed four subtypes: Immune Inert, Neutral, Active, and Responsive. ( D ) Differential treatment responses assessed by Kaplan-Meier survival analysis of the WFCCC cohort, using distant-metastasis-free survival time as the index. Survival curves of the Immune Neutral (top) and Active (bottom) Subtypes under different treatments are presented and labeled with patient numbers and log-rank test p-values. More details are given in the Supplement.

    Article Snippet: The underlying mechanisms of the discovered modules were revealed by gene set enrichment analysis using BioCarta signaling pathway signatures .

    Techniques: Labeling